AzTrials
AzTrials

DeliriumNCT05891873

Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations

An observational study of Delirium, run by Masaryk University at 1 site in Czechia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Intensive and critical care in the intensive care unit (ICU) is often associated with ICU delirium and post-ICU dementia, regardless of the nature of the primary disease or insult. Read more about this study

Who is it for?
Any age
Conditions the study is for
Delirium
What is being tested?
CAM-ICU, ICDSC and 4AT
How many people
700 participants
Where
1 siteCzechia
Study dates
7 Sep 2023to Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Neurointensive/neurocritical group (N-ICU): patients with acute ischaemic or haemorrhagic stroke admitted to the Stroke Unit or ICU of the Department of Neurology, University Hospital Brno (NK-UHB). Paediatric intensive/critical group (P-ICU): children aged 6-18 years, admitted to the Paediatric ICU - Department of Paediatric Anaesthesiology and Intensive Care (KDAR-UHB) with a stay of at least 24 hours (including postoperative care).

Who may be able to join

  • Neurointensive/neurocritical group (N-ICU): patients with acute ischaemic or haemorrhagic stroke admitted to the Stroke Unit or ICU of the Department of Neurology, University Hospital Brno (NK-UHB).
  • Paediatric intensive/critical group (P-ICU): children aged 6-18 years, admitted to the Paediatric ICU - Department of Paediatric Anaesthesiology and Intensive Care (KDAR-UHB) with a stay of at least 24 hours (including postoperative care).

Who cannot join

  • (N-ICU) severe trauma with short life expectancy (days)
  • duration of the ICU stay shorter than 24 hours

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Josef Bednařík, prof. MD, CSc. contact

532231481

bednarik.josef@fnbrno.cz

Lucia Bakošová, MD contact

532232503

bakosova.lucia@fnbrno.cz

Czechia1 site, 1 recruiting
  • Brno University Hospital

    Brno, 62500

    Josef Bednařík, prof. MD, CSc., 532231481, bednarik.josef@fnbrno.cz

    Recruiting

Other trials in Czechia

About this study

Intensive and critical care in the intensive care unit (ICU) is often associated with ICU delirium and post-ICU dementia, regardless of the nature of the primary disease or insult. Optimal practical management of ICU delirium including its screening, prevention, and treatment, is an integral part of the current recommendations for optimal ICU care, but there are large gaps in the knowledge about the optimal and most effective prevention and treatment of this complication. Information on the actual implementation of these recommendations in the Czech Republic is lacking. The diagnosis of delirium is particularly challenging in neurointensive care patients (due to overlap with symptoms of primary brain lesions) and in a paediatric population. A complementary multicentre observational 4-year follow-up study, performed in an adult neurointensive/critical care stroke cohort and in a paediatric intensive/critical care cohort in centres following currently recommended preventive measures (Delusion-deep-cz) will investigate the incidence of ICU delirium and post-ICU dementia and their modifiable and non-modifiable predisposing and precipitating risk factors. Objectives are to determine the optimal methods for diagnostic screening of these complications and for the differential diagnosis of conditions mimicking delirium (non-convulsive epileptic state) or symptoms hindering its diagnosis (aphasia), and to study the association between sleep disturbances and ICU delirium to verify the role of sleep in the pathophysiology of delirium.

Read the detailed description

Design

  • Multicentre observational follow-up cohort study with 2 different cohorts and a minimum follow-up period of 6 months.

Recruitment (groups)

  1. Neurointensive/neurocritical group (N-ICU): patients with acute ischaemic or haemorrhagic stroke admitted to the Stroke Unit or ICU of the Department of Neurology, University Hospital Brno (NK-UHB).
  2. Paediatric intensive/critical group (P-ICU): children aged 6-18 years, admitted to the Paediatric ICU - Department of Paediatric Anaesthesiology and Intensive Care (KDAR-UHB) with a stay of at least 24 hours (including postoperative care).

General working hypotheses

  • Current recommendations for the practical management (PADIS) and prevention of delirium lead to a decrease in the incidence of ICU-delirium and post-ICU dementia and may also change the spectrum of significant risk factors.
  • In the Czech Republic, both general knowledge and practical implementation of these recommendations may be low.
  • Currently recommended screening instruments for ICU-delirium are valid and reliable in both adult and paediatric cohorts of (neuro)intensive/critical patients and can replace the expert assessment using DSM-IV or V criteria (The Diagnostic and Statistical Manual of Mental Illnesses).
  • Non-convulsive status epilepticus (NCSE) may mimic ICU-delirium and a routine EEG exam in patients meeting the criteria for ICU delirium may be helpful.
  • Aphasia may complicate the diagnosis of delirium and may prevent the use of the current screening tools for delirium in neurointensive care patients.
  • Sleep disturbances in ICU patients are often associated with the development of ICU delirium and evaluating the time course of these conditions may reveal their possible causal relationship.

Outcomes Primary outcomes

  • Development of ICU delirium Secondary outcomes
  • Length of stay in ICU
  • Case-fatality risk
  • Post-ICU dementia (BDS, Blessed dementia scale)
  • Degree of functional dependency (Barthel index)

Objectives

  • To review the incidence and significant modifiable and non-modifiable predisposing and precipitating risk factors for ICU delirium and post-ICU dementia in general and neuro-intensive/critical care in adult and paediatric populations treated in health care facilities according to current recommendations for prevention of these complications (ABCDEF bundle).
  • To verify optimal methods for diagnostic screening of ICU delirium: CAM-ICU (The confusion assessment method for the ICU), 4AT (Rapid clinical test for delirium detection - 4AT) and ICDSC (Intensive care delirium screening checklist) in adult populations and pCAM-ICU (paediatric confusion assessment method for the ICU), psCAM-ICU (pre-school confusion assessment method for the ICU) and CAPD (Cornell Assessment of Pediatric Delirium) in paediatric populations to screen for delirium.
  • To verify optimal methods for the differential diagnosis of conditions that mimic or complicate the diagnosis of ICU delirium: NCSE, aphasia,
  • To investigate associations between sleep disturbances and ICU-delirium to confirm their role in the pathophysiology of delirium.
Conditions
Delirium
Being tested
CAM-ICU, ICDSC, 4AT, p(s)CAM-ICU, CAPD
Keywords
delirium, delirium screening, ICU delirium
Medical subject headings
Delirium

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CAM-ICUDiagnostic test

    Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

  • ICDSCDiagnostic test

    Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

  • 4ATDiagnostic test

    Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

  • p(s)CAM-ICUDiagnostic test

    Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

  • CAPDDiagnostic test

    Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

  • MASTcz (The Mississippi Aphasia Screening Test)Diagnostic test

    People with aphasia will be examined by a skilled speech therapist.

  • EEGDiagnostic test

    Patients with positive delirium will undergo EEG examination. 10-min native EEG.

Study groups in NCT05891873
Study groupRoleWhat they receive
Neurointensive/neurocritical group (N-ICU)Not described
Receives: Diagnostic Test: CAM-ICU; Diagnostic Test: ICDSC; Diagnostic Test: 4AT; Diagnostic Test: MASTcz (The Mississippi Aphasia Screening Test); Diagnostic Test: EEG
Paediatric intensive/critical group (P-ICU)Not described
Receives: Diagnostic Test: p(s)CAM-ICU; Diagnostic Test: CAPD; Diagnostic Test: EEG

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants who develop ICU delirium

    assessed by experienced neuro-intensivist

    Measured: up to 14 days after admission

Secondary outcomes (4)
  1. Length of stay in ICU

    Measured: up to 10 weeks

  2. Mortality

    Measured: 6 months

  3. Number of participants and severity of post-ICU dementia, cognitive impairment(Blessed dementia scale, BDS)

    Measured: 6 months

  4. Degree of functional dependency (Barthel index)

    the higher score, the worse result meaning cognitive impairment and non-independence

    Measured: up to 10 weeks and after 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jun 2023
  2. Study start7 Sep 2023
  3. Primary completionMay 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
700 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05891873
Sponsor's protocol ID
DELUSION-DEEP-CZ
Status last verified
Oct 2023
First submitted
17 May 2023
Last updated
23 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Delirium, run by Masaryk University at 1 site in Czechia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Josef Bednařík, prof. MD, CSc. (532231481, bednarik.josef@fnbrno.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants who develop ICU delirium (time frame: up to 14 days after admission). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in